Evidence map›Paper›PMID 31042762›Full record

ArticlePloS one2019

A novel sequencing-based vaginal health assay combining self-sampling, HPV detection and genotyping, STI detection, and vaginal microbiome analysis.

Elisabeth M Bik, Sara W Bird, Juan P Bustamante, Luis E Leon, Pamela A Nieto, Kwasi Addae, Víctor Alegría-Mera, Cristian Bravo, Denisse Bravo, Juan P Cardenas and 30 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 1 institution in 1 country.

Elisabeth M BikuBiome, San Francisco, CA, United States of America.ORCID 0000-0001-5477-0324
Sara W BirduBiome, San Francisco, CA, United States of America.
Juan P BustamanteuBiome, San Francisco, CA, United States of America.
Luis E LeonuBiome, San Francisco, CA, United States of America.
Pamela A NietouBiome, San Francisco, CA, United States of America.
Kwasi AddaeuBiome, San Francisco, CA, United States of America.
Víctor Alegría-MerauBiome, San Francisco, CA, United States of America.
Cristian BravouBiome, San Francisco, CA, United States of America.
Denisse BravouBiome, San Francisco, CA, United States of America.
Juan P CardenasuBiome, San Francisco, CA, United States of America.
Glenn A CarsonuBiome, San Francisco, CA, United States of America.
Adam CaugheyuBiome, San Francisco, CA, United States of America.
Paulo C CovarrubiasuBiome, San Francisco, CA, United States of America.
José Pérez-DonosouBiome, San Francisco, CA, United States of America.
Graham GassuBiome, San Francisco, CA, United States of America.
Sarah L GuptauBiome, San Francisco, CA, United States of America.
Kira HarmanuBiome, San Francisco, CA, United States of America.
Donna Marie B HongouBiome, San Francisco, CA, United States of America.
Juan C JiménezuBiome, San Francisco, CA, United States of America.
Laurens KraaluBiome, San Francisco, CA, United States of America.
Felipe Melis-ArcosuBiome, San Francisco, CA, United States of America.
Eduardo H MoralesuBiome, San Francisco, CA, United States of America.
Amanda MortonuBiome, San Francisco, CA, United States of America.
Camila F NavasuBiome, San Francisco, CA, United States of America.
Harold NuñezuBiome, San Francisco, CA, United States of America.
Eduardo OlivaresuBiome, San Francisco, CA, United States of America.
Nicolás Órdenes-AenishanslinsuBiome, San Francisco, CA, United States of America.
Francisco J OssandonuBiome, San Francisco, CA, United States of America.
Richard PhanuBiome, San Francisco, CA, United States of America.
Raul PinouBiome, San Francisco, CA, United States of America.
Katia Soto-LiebeuBiome, San Francisco, CA, United States of America.
Ignacio VarasuBiome, San Francisco, CA, United States of America.
Patricia Vera-WolfuBiome, San Francisco, CA, United States of America.
Nathaniel A WaltonuBiome, San Francisco, CA, United States of America.
Daniel E AlmonaciduBiome, San Francisco, CA, United States of America.
Audrey D GoddarduBiome, San Francisco, CA, United States of America.
Juan A UgaldeuBiome, San Francisco, CA, United States of America.
Susan ZneimeruBiome, San Francisco, CA, United States of America.
Jessica RichmanuBiome, San Francisco, CA, United States of America.
Zachary S ApteuBiome, San Francisco, CA, United States of America.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The composition of the vaginal microbiome, including both the presence of pathogens involved in sexually transmitted infections (STI) as well as commensal microbiota, has been shown to have important associations for a woman's reproductive and general health. Currently, healthcare providers cannot offer comprehensive vaginal microbiome screening, but are limited to the detection of individual pathogens, such as high-risk human papillomavirus (hrHPV), the predominant cause of cervical cancer. There is no single test on the market that combines HPV, STI, and microbiome screening. Here, we describe a novel inclusive vaginal health assay that combines self-sampling with sequencing-based HPV detection and genotyping, vaginal microbiome analysis, and STI-associated pathogen detection. The assay includes genotyping and detection of 14 hrHPV types, 5 low-risk HPV types (lrHPV), as well as the relative abundance of 31 bacterial taxa of clinical importance, including Lactobacillus, Sneathia, Gardnerella, and 3 pathogens involved in STI, with high sensitivity, specificity, and reproducibility. For each of these taxa, reference ranges were determined in a group of 50 self-reported healthy women. The HPV sequencing portion of the test was evaluated against the digene High-Risk HPV HC2 DNA test. For hrHPV genotyping, agreement was 95.3% with a kappa of 0.804 (601 samples); after removal of samples in which the digene hrHPV probe showed cross-reactivity with lrHPV types, the sensitivity and specificity of the hrHPV genotyping assay were 94.5% and 96.6%, respectively, with a kappa of 0.841. For lrHPV genotyping, agreement was 93.9% with a kappa of 0.788 (148 samples), while sensitivity and specificity were 100% and 92.9%, respectively. This novel assay could be used to complement conventional cervical cancer screening, because its self-sampling format can expand access among women who would otherwise not participate, and because of its additional information about the composition of the vaginal microbiome and the presence of pathogens.

Indexed as

MicrobiotaAdolescentAdultCapsid ProteinsDNA, ViralFemaleGardnerellaGenotypeHumansLactobacillusLimit of DetectionMiddle AgedOncogene Proteins, ViralPapillomaviridaePapillomavirus InfectionsReproducibility of ResultsCapsid ProteinsDNA, ViralHPV L1 protein, Human papillomavirusOncogene Proteins, ViralRNA, Ribosomal, 16S

Identifiers

PMID31042762
PMCPMC6493738
OpenAlexW2950411683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.